Zevra Therapeutics (ZVRA)

• Market cap: $403M
• 1 day: -2.87%
• 5 days: -6.88%
• 1 month: 1.50%
• 3 months: -13.39%
• 6 months: 3.62%
• Year to date: -15.07%
• 1 year: 47.91%
• 5 years: 132.50%
• 10 years: -95.85%
• Sector: Healthcare
• Industry: Biotechnology

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

634% more call options, than puts

Call options by funds: $3.95M | Put options by funds: $539K

122% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 18

41% more capital invested

Capital invested by funds: $201M [Q3] → $283M (+$81.5M) [Q4]

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

8.42% more ownership

Funds ownership: 55.07% [Q3] → 63.49% (+8.42%) [Q4]

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

0% more funds holding

Funds holding: 108 [Q3] → 108 (+0) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $18 142% upside
• Avg. target: $22 196% upside
• High target: $25 236% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Sumant Kulkarni 0% 1-year accuracy 0 / 8 met price target	236% upside $25	Buy Maintained	13 Mar 2025
Guggenheim Eddie Hickman 22% 1-year accuracy 2 / 9 met price target	196% upside $22	Buy Maintained	13 Mar 2025
HC Wainwright & Co. Oren Livnat 40% 1-year accuracy 2 / 5 met price target	169% upside $20	Buy Reiterated	13 Mar 2025
Citizens Capital Markets Jason Butler 19% 1-year accuracy 8 / 42 met price target	142% upside $18	Market Outperform Maintained	12 Mar 2025
Cantor Fitzgerald Kristen Kluska 25% 1-year accuracy 27 / 106 met price target	236% upside $25	Overweight Reiterated	12 Mar 2025